Building Brand Awareness

Blog

Third Quarter 2023 Updates, 
Including Our New Mission Statement

November 14, 2023

During the third quarter, we refined our mission statement to better capture the spirit of what we endeavor to do each day here at Cumberland Pharmaceuticals. It now reads as follows: working together to provide unique products that improve the quality of patient care We...

Second Quarter 2023 Updates, Including Expanded FDA Approval for Caldolor® and Publication of Newborn Clinical Study Results

August 14, 2023

In the second quarter of 2023, we advanced our business, as the operating environment continued to slowly improve from the post-pandemic challenges. Our team has been working diligently to maximize the potential of our commercial brands, progress our pipeline and pursue select acquisitions. We’re pleased...

First Quarter 2023 Updates, Including NOPAIN Act and FDA Fee Waiver

May 16, 2023

We have continued to successfully manage our business despite the challenges in our operating environment. Our team has remained dedicated to delivering high-quality medicines for our patients, while also developing new medicines for the future. We’re pleased to share several notable developments from the first...